Fubotv earnings beat by $0.10, revenue topped estimates
On Tuesday, Elevation Oncology (NASDAQ:ELEV) shares maintained a Market Perform rating from Citizens JMP analysts, following news of the company’s acquisition by Tang Capital’s Concentra. The purchase price of $0.36 per share, along with a contingent value right (CVR), represents a 13% premium over the stock’s closing price last Friday. According to InvestingPro data, the stock has shown a significant 26% return over the past week, though it remains down 89% over the last year.
The acquisition by Concentra concludes Elevation Oncology’s search for strategic alternatives, which began after the company decided to halt the development of its leading CLDN18.2-targeting ADC asset due to unsatisfactory results in monotherapy. Citizens JMP analysts have expressed that they do not foresee the emergence of a competing buyer or the possibility of a reverse merger for Elevation Oncology. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 19.4, despite its recent challenges.
The analysts’ Market Perform rating is based on the current trading price of Elevation Oncology’s shares at $0.38. This valuation includes an approximate $0.02 per share value for the CVR, which the analysts consider to be fair. The decision to maintain the Market Perform rating reflects the analysts’ view that the acquisition terms are reasonable and that the market has appropriately priced the stock given the recent developments.
Elevation Oncology’s strategic review and subsequent acquisition come as a pivotal moment for the company, which has faced challenges with its main drug asset. The Market Perform rating indicates that while the firm acknowledges the acquisition, it sees limited potential for further stock movement in the near term.
In other recent news, Elevation Oncology has announced a definitive merger agreement with Concentra Biosciences, LLC. Under this agreement, Concentra will acquire Elevation Oncology for $0.36 in cash per share, along with a non-tradeable contingent value right (CVR) tied to future proceeds from the asset EO-1022. The Board of Directors at Elevation Oncology has unanimously approved the merger, which is expected to close in July 2025, pending certain conditions, including the tender of a majority of shares. In related developments, TD Cowen analyst Marc Frahm has downgraded Elevation Oncology’s stock from Buy to Hold, citing the acquisition as a favorable option for shareholders and noting challenges in the company’s current financial environment. Additionally, Elevation Oncology has opted to prepay a $30 million term loan ahead of schedule, demonstrating its financial capability and strategic debt management. The company has also revealed promising preclinical data for its HER3 antibody-drug conjugate, EO-1022, which will be presented at the American Association for Cancer Research Annual Meeting 2025. These developments highlight Elevation Oncology’s strategic moves and ongoing efforts in advancing its oncology pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.